Sanofi Posts $794M Loss Despite 7% Revenue Jump

Sanofi reported Q4 2025 earnings marked by a significant net loss despite revenue growth. The company exceeded revenue estimates but missed net income expectations, while guiding for high single-digit sales growth in 2026.

Revenue

Sanofi’s total revenue rose 7.0% to $11.30 billion in Q4 2025, driven by its Biopharma segment, which contributed $11.30 billion. Other segments supplemented this with $902 million, while the Total group revenue reached $12.21 billion. The performance highlights the company’s reliance on its core pharmaceutical operations.

Earnings/Net Income

Sanofi swung to a $0.66 per-share loss in Q4 2025, a 265.0% negative change from the prior year’s $0.40 profit. Net income deteriorated to a $794 million loss, reflecting a 255.4% decline from $511 million in 2024 Q4. Despite the loss, the company has maintained profitability for eight consecutive years in the corresponding quarter, underscoring long-term stability.

Despite a 7% revenue rise, Sanofi's net loss of $794M marked a 255% deterioration, underscoring operational challenges.

Price Action

The stock price of Sanofi has edged down 0.26% during the latest trading day, has edged down 0.65% during the most recent full trading week, and has dropped 4.68% month-to-date.

Post-Earnings Price Action Review

The strategy of buying SNY when earnings beat and holding for 30 days resulted in poor performance. The strategy had a -12.36% return, compared to a 51.10% return for the benchmark, and a maximum drawdown of 32.17%, indicating significant risk and underperformance.

CEO Commentary

Paul, CEO of Sanofi, emphasized 2025 as a year of strategic progress, driven by the Opella transaction and a €5 billion share buyback program. He highlighted innovation milestones, including the blockbuster ALTUVIIIO (€1.2 billion) and Dupixent (€15.7 billion annual sales). Strategic acquisitions, such as Vicebio and Dynavax, were cited to strengthen vaccines for older adults and RSV. Paul underscored Sanofi’s role in developing PAS 2090, a sustainability standard for medicines, and expressed optimism about future growth through R&D and commercial execution. The tone was confident, stressing disciplined capital allocation and market leadership in biologics and vaccines.

Guidance

Sanofi expects 2026 full-year sales growth of high single digits and business EPS growth slightly faster than sales, with EPS guidance inclusive of a €1 billion share buyback program. François, CFO, noted vaccine sales may decline modestly, while R&D expenses will increase moderately, with placeholders for potential acquisitions. Free cash flow is targeted to reach 20% of net sales by 2026, supported by inventory optimization. The guidance accounts for portfolio divestments reducing sales by ~€200 million and a €500 million capital gain from asset disposals. Tax rates and operational leverage were cited as stable contributors to profitability.

Additional News

Sanofi announced a €1 billion share buyback program in 2026, signaling confidence in its capital structure. The company also completed strategic acquisitions, including Vicebio and Dynavax, to bolster its vaccine portfolio for aging populations and RSV. Additionally, Sanofi unveiled PAS 2090, a sustainability standard for medicines, aligning with global ESG trends. These moves reflect its focus on disciplined capital allocation and long-term value creation.